Pioglitazone Research Paper

Satisfactory Essays
Pioglitazone was also introduced in 1999 for treating type 2 diabetes mellitus. It improves glycaemic control and LDL cholesterol and also high-density lipoprotein (HDL) cholesterol ratio compared the placebo. It does not cause hepatotoxicity. There is no evidence that pioglitazone causes adverse cardiovascular effects. In fact, it has shown a beneficial effect on cardiovascular disease. Its combination with aliskiren (direct rennin inhibitor) is being considered as a possible therapeutic intervention for cardiovascular injury
Get Access